Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 7 of 11
Apr 3, 2026In a strategic move to facilitate better nutritional health, Amazon has teamed up with Berry Street to offer insurance-covered nutrition therapy services through its platform, aiming to increase accessibility and awareness among users. This development reflects the growing significance of nutrition therapy in healthcare.
Dr. Priya Nandakumar
Mar 29, 2026The assessment of return on investment (ROI) for AI initiatives within health systems is undergoing a significant transformation. As budgetary pressures intensify, leaders are adopting expanded frameworks that value not only direct cost savings but also indirect benefits like improved clinician well-being and operational efficiencies, marking a paradigm shift in how these technologies are integrated.
Michael Torres
Mar 24, 2026Rachel Springate of Muse Capital explains why pure DTC approaches rarely succeed in healthcare. Companies that start with patient needs and integrate clinical data and payers show a promising new path for healthcare startups.
Michael Torres
Mar 22, 2026The infusion of new capital into Lantern highlights ongoing interest and confidence in innovative healthcare solutions tailored to employers and insurers. Such investment initiatives often aim to improve healthcare delivery and cost management through strategic technology development and partnerships.
Sophia Reynolds
Mar 19, 2026The 2026 labor market within the U.S. life sciences sector reflects a dynamic workforce environment where job mobility has become a critical strategy for salary advancement. A new BioSpace report highlights the substantial financial benefits for those switching employers amid ongoing economic pressures and industry recalibration.
Dr. Priya Nandakumar
Mar 18, 2026The pharmaceutical sector is currently characterized by a cautious approach towards deals, with a preference for mid-sized transactions. Industry experts argue that, given the substantial capital reserves, there may be a strategic imperative to consider larger scale mergers and acquisitions to strengthen competitive positioning and innovation capacity.
Sophia Reynolds
Mar 10, 2026The recent funding round led by Breakout Ventures highlights growing investor interest in artificial intelligence applications within biotechnology. This fund focuses on early-stage companies, a segment seeing increasing investor interest despite a broader market trend favoring derisked assets. The infusion of capital reflects confidence in AI-driven drug discovery's transformative potential.
Dr. Alex Morgan
Mar 5, 2026With the raising of substantial capital, Science Corp. is poised to bring forward a transformative medical device aimed at restoring vision. This funding milestone underscores strong investor confidence as the company awaits the FDA's critical decision on the PRIMA retinal implant.
Michael Torres
Mar 5, 2026The breakdown in contract negotiations between Mount Sinai and Anthem Blue Cross Blue Shield highlights the broader challenges faced by payers and providers amid escalating healthcare costs and administrative complexities. This separation further underscores the critical need for innovative strategies to manage and control healthcare expenses effectively.
Sophia Reynolds
Mar 4, 2026The latest infusion of venture capital into biotech reflects growing interest in novel therapies for inflammatory bowel diseases. Following promising Phase 2b results demonstrating sustained clinical remission, Teva’s project has attracted major backing to support further clinical development and potential market entry.
Sophia Reynolds
Mar 4, 2026The recent Series D funding round for Grow Therapy underscores a growing industry focus on scalable mental health solutions integrated with employer and health system networks. This capital infusion aims to broaden Grow Therapy's footprint in connecting patients to necessary mental health care resources, thereby addressing increasing demand.
Dr. Priya Nandakumar
Mar 3, 2026The health tech sector continues its upward trajectory with robust funding rounds reported in February 2026. This article highlights five notable investments that reflect the evolving landscape where technology is reshaping healthcare delivery and patient management.
Dr. Alex MorganMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.